Financial Performance and Subsidiaries Revenue
US MARKET FOCUS- COMPLEX GENERICS & FRONTEND
Predominantly focused on high-barrier-to-entry products that are typically characterized by one or more of the
following:
Challenging delivery systems
Intricate Chemistry
◉
Difficult or complex manufacturing process
Will continue to work with partners for complex products or those involving unique patent challenges
Low risk business model; through partnerships with global pharmaceutical players
■ Marketing partner typically responsible for litigation and regulatory process to secure ANDA approval.
Multi-site approvals
☐
Multi-sourcing arrangements
Launched Ondansetron and Nitroglycerin through NATCO Pharma USA LLC; Armodafinil to be launched soon
PIPELINE OF NICHE IN THE US
Revlimid
Key Brand
Copaxone
Tamiflu
KEY PRODUCTS IN THE PORTFOLIO (1)
Afinitor(2.5 mg, 5 mg, 7.5
mg and 10 mg)
Fosrenol
Doxil
Tykerb
Zortress
Molecule
Lenalidomide
Glatiramer Acetate
Oseltamivir
Everolimus (higher
strength)
Lanthanum Carbonate
Liposomal Doxorubicin
Lapatinib Ditosylate
Everolimus (lower strength)
NATCO
Therapeutic Segment
/ Primary Indication
Cancer/Multiple Myeloma
CNS/Multiple Sclerosis
Anti-Viral/Influenza
Cancer/Breast
Renal disease
Cancer/Ovarian and other
Cancer/Breast
Immunosupressant/Organ
Transplant
19 Para IVs in the pipeline (2)
Of which 7 are approved (2) (either tentative or fully)
Key Brand
SOLO FIRST TO FILE IN THE PIPELINE (1)
Eliquis
Key Brand
Molecule
Therapeutic Segment / Primary Indication
Ozempic
Lynparza
Tracleer
Kyprolis
Imbruvica
Zydelig
Bosentan (32mg)
Anti-hypertensive
Kyprolis
Carfilzomib (10mg)
Cancer/Multiple Myeloma
Ibrutinib (tablet)
Cancer/Leukaemia
Pomalyst
Idelalisib
Cancer
Lonsurf
Lynparza
Olaparib
Ovarian/Breast Cancer
Ozempic
Balversa
Semaglutide pen (8mg/3ml)
Erdafitinib
Diabetes
Yondelis
Trabectedin
Bladder Cancer
Calquence
Zydelig
Idelalisib
Imbruvica
Carfilzomib
Ibrutinib
Pomalidomide
Trifluridine/Tipracil
Acalabrutinib
Ovarian/Breast Cancer
Cancer/Multiple Myeloma
Cancer/Leukaemia
Cancer/Multiple Myeloma
Metastatic colorectal cancer
Advanced soft-tissue sarcoma/
ovarian cancer
Cancer/Blood
Cancer
KEY PARA IV PRODUCTS IN THE PIPELINE (1)
Therapeutic Segment / Primary
Indication
Anticogulant
Molecule
Apixaban
Semaglutide pen
Olaparib
Diabetes
1.As of June 30, 2023
2. As of June 30, 2023. Approval received either by Natco or its marketing partner
6View entire presentation